2019
“Antisense Technology: Today and Tomorrow” keynote speaker at TIDES: Oligonucleotide &
Peptide Therapeutics, San Diego CA, May 21, 2019
2018
“Coupling Genomics, Biological Insights and Antisense to Expedite Drug Discovery and Development” plenary speaker at Bridging the Gap: Translating Genomic Discovery into Human Therapeutics, Ionis’ Exhibitor Education Event, American Society of Human Genetics conference, San Diego CA, October 16, 2018.
“Antisense Technology: Past, Present & Future”, keynote at RNA at the Bench and Bedside, Nature Conference, San Deigo, CA, October 8-10, 2018.
2017
“Antisense Technology: Past, Present & Future”, award address presented to the Division of Medicinal Chemistry at the American Chemical Society National Meeting, San Francisco, CA, April 4, 2017.
2016
“Antisense Technology: Present & Future”, plenary presentation at the Canton Nucleic Acid Forum, Guangzhou, China, November 10, 2016.
“Antisense Technology: Present & Future” plenary presentation, Lifetime Achievement Award at the Oligoneucleatide Therapeutics Society, Montreal, Quebec, Canada, September 28, 2016.
2015
“Building Isis: Experiments in Technology, Business Model and Culture” at Keck Graduate Institute of Applied Sciences, Claremont, CA, February 27, 2015.
“Antisense Technology: Current Status and Future”, keynote speaker at TIDES 2015, San Diego, CA, May 4, 2015.
2014
“The Human RNase H1 Degradasome, Biological Roles and Roles in Antisense Pharmacology”, panel speaker at Koch Institute 2014 Symposium: RNA Biology, Cancer and Therapeutic Implications at MIT, Boston, MA, June 13, 2014.
“Disruptive Technologies for Drug Discovery”, Symposium Panel speaker at BIO International Convention, San Diego, CA, June 23-26, 2014.
2013
“Antisense Technology: Past, Present, Future”, Keynote Address at American Chemical Society Annual Meeting [ACS], San Diego, CA, June 13, 2014.
2012
“Antisense Technology: Past, Present, Future”, Plenary Lecture at Oligonucleotide Therapeutics Society, Boston, MA, October 28, 2012.
2009
“Antisense Technology: Past, Present, Future”, Keynote Address at Keystone Symposia, Lake Louise, Alberta, Canada, February 8, 2009.
2008
“The Outlook for Personalized Medicine”, Keynote Address at Analytical & Life Science Systems Association 2008 Senor Management Conference, San Francisco, October 6, 2008.
“The Biotech Tango: Science, Drugs, Strategy and Finance – A Recent Case History”, Keynote Address at Allicense Conference, San Francisco, CA, May 13, 2008.
2007
“Antisense Technology: The End of the Beginning”, Keynote Address at 2007 AAPS National Biotechnology Conference, San Diego Convention Center, San Diego, June 27, 2007.
2006
“Advances in Antisense Technology: Drug Discovery and Development: The End of the Beginning”, Keynote Address at Texas Club of Internal Conference, Learning Center, Continuing Medical Education, UC San Diego School of Medicine, October 10, 2006.
2005
“Antisense Technology: The End of the Beginning Molecular Pharmacology”, Keynote Address at FDA Center for Drug Evaluation and Research Symposium on Antisense and Oligonucleotide Therapeutics, University of Maryland Shady Grove Campus, Rockville, MD, November 1, 2005.
“Antisense Technology: The End of the Beginning Molecular Pharmacology”, United States Patent Office, Alexandria, VA, November 2, 2005.
2004
“Antisense Therapeutics: The End of the Beginning”, Molecular Based Technologies Therapeutics Symposium, Pfizer, Groton, CT, October 5, 2004.
2003
“The Challenge of Genomic Based Drug Discovery”, Needham Conference, The Palace Hotel, New York, NY., June 5, 2003.
“Drug Discovery and Development Panel – Second Generation Druggable Targets”, BIO2003 Convention, Washington Convention Center, Washington, D.C., June 23, 2003.
“Merging Lanes: How to Drive a Deal on the Road to Success – BIO2003 Business Development 1 Panel” BIO2003 Convention, Washington Convention Center, Washington, D.C., June 23, 2003.
2002
“Isis Pharmaceuticals – The RNA Company,” Bio CEO 2002 Conference, The Waldorf-Astoria Hotel, New York, NY, February 20, 2002.
“Enhancing the Productivity of the Pharmaceutical Industry”, BioBusiness Asia 2002 Conference, Far Eastern Plaza Hotel, Taipei, Taiwan, February 28, 2002.
“Creating a Biotech Company: Where Science is Taking Us”, Indiana Health Industry Conference, Indianapolis, IN, June 4, 2002.
“Structure and Function of Human RNaseHs”, 6th International Meeting on Ribonucleases, Bath, United Kingdom, June 20, 2002.
“Antisense Therapeutics: The End of the Beginning”, Murdock Childrens Research Institute, Royal Childrens Hospital, Parkville, Australia, August 19, 2002.
“The Art of Strategic Corporate Partnering”, AusBiotech 2002 National Biotechnology Conference and Investment Forum, Melbourne Convention Center, Melbourne, Australia, August 20, 2002.
“Improving the Productivity of the Drug Discovery and Development Industry”, 2nd Annual Yale Biotech Conference, New Haven Lawn Club, New Haven, CT, September 20, 2002.
“Antisense Therapeutics: The End of the Beginning”, Alfred Burger Lecture for the 2002-2003 Academic Year, University of Virginia, Charlottesville, VA, October 1, 2002.
2001
“Some Thoughts About Drug Discovery and Development,” CSUPERB’s 13th Annual California State University System Biotechnology Symposium, The Kellogg Conference Center, Pomona, CA, January 12, 2001.
“Isis Pharmaceuticals – The RNA Company,” 13th Annual Roth Capital Partners Growth Stock Conference, The Ritz-Carlton, Laguna Niguel, CA, February 20, 2001
“Biotechnology is Ushering in a New Paradigm in Medicine for the Treatment of Disease,” Fortis Bank Biotechnology Symposium, Schloss Kronberg, Germany, March 21, 2001
“Isis Pharmaceuticals – The RNA Company,” 4th Annual Tucker Anthony Sutro Life Sciences and Health Care Conference, Dana Point, the Ritz-Carlton, Laguna Niguel, CA, April 5, 2001
“Isis Pharmaceuticals – The RNA Company,” Wells Fargo Van Kasper San Diego Growth Stock Conference, Wyndham Emerald Hotel, San Diego, CA, June 18, 2001.
“The Drug Discovery and Development Industry”, NIH-Supported Fellows Program at BIO2001, Town & Country Hotel, San Diego, CA, June 23, 2001
“Antisense Self Targeting”, 28th International Symposium on Controlled Release of Bioactive Materials and Conference on Consumer and Diversified Products Conference, Hyatt Regency Hotel, San Diego, CA, June 24, 2001.
“Isis Pharmaceuticals – The RNA Company,” UBS Warburg Global Life Sciences Conference, The Pierre Hotel, New York, NY, October 8, 2001.
“The Post-Genomic Drug Discovery and Development Industry”, Heart Institute Annual Banquet, San Diego Yacht Club, San Diego, CA, November 16, 2001.
“Isis Pharmaceuticals – The RNA Company,” Robertson Stephens Medical Conference, The Pierre Hotel, New York, NY, November 29, 2001.
2000
“Isis Pharmaceuticals,“ U.S. Bancorp Piper Jaffray Health Care Conference, Pierre Hotel, New York, NY, February 1-3, 2000.
“Investment in New Drug Discovery Technologies and Approaches to Development,” International Conference on Drug Development, Barton Creek Conference Center, Austin, TX, February 21, 2000.
“Isis Pharmaceuticals,” Twelfth Annual Cruttenden Roth Growth Stock Conference, The Ritz-Carlton, Laguna Niguel, CA, February 23, 2000.
“Antisense Technology: The End of the Beginning,” 10th Annual Medical Scientist Training Program Seminar Series, UCSD, La Jolla, CA, March 14, 2000.
“Isis Pharmaceuticals – The RNA Company,” Credit Suisse First Boston West Coast Biotechnology Field Trip, The Regent Beverly Wilshire, Beverly Hills, CA, March 31, 2000.
“Isis Pharmaceuticals – The RNA Company,” Sutro & Co. Health Care Conference, Four Seasons Hotel, Newport Beach, CA, April 6, 2000.
“Antisense Technology: The End of the Beginning”, IBC Tides 2000 – Oligonucleotide and Peptide Technology Conference, Caesar’s Palace, Las Vegas, NV, May 9-12, 2000.
“Development Project Management at Isis”, Drug Information Association 36th Annual Meeting, San Diego Convention Center, San Diego, CA, June 12-13, 2000.
“Capturing Value from Genomics”, NASDAQ Biotech Summit, Haas School of Business-UC Berkeley, Berkeley, CA, June 27, 2000.
“Isis Pharmaceuticals – The RNA Company,” Solomon Smith Barney Health Care Conference, Marriott Marquis Hotel, New York, NY, October 18, 2000.
“Isis Pharmaceuticals – The RNA Company,” Robertson Stephens Medical Conference, The Pierre Hotel, New York, NY, November 27, 2000.
1999
“Financing Biotechnology in 1999,” UCSD Connect’s 1999 Capital Markets Outlook, Sheraton Grande Torrey Pines, San Diego, CA, January 28, 1999.
“Investing in Antisense: From Genes to Hope for Patients,” 60th NYSSA Investing in Cancer Research Seminar: “From Hopes to Cures,” New York, NY, February 22, 1999.
“Isis Pharmaceuticals,“ Cowen & Company Nineteenth Annual Health Care Conference, Boston, MA, March 9-11, 1999.
“Antisense Technology: The End of the Beginning,” Nineteenth Annual Meeting of the AACR, Meet the Expert Sunrise Session, Philadelphia, PA, April 13, 1999.
“Antisense Technology: The End of the Beginning,” Gene Therapy Conference, Redwood City, CA, April 18, 1999.
“Antisense Technology: The End of the Beginning,” IBC’s 6th International Conference on Oligonucleotide Therapeutics, Hilton, La Jolla, CA, May 3, 1999.
”Breakthrough Thinking,” Medical Marketing Association Second Century of the Drug and Development Industry, Westin Harbor Island, San Diego, CA, June 3, 1999.
“Antisense Technology: The End of the Beginning,” DOE Workshop Imaging Expression, San Diego Marriott, La Jolla, CA, June 16-17, 1999.
“Investing in Antisense,” National Association of Stockbrokers, San Francisco, CA, September 29, 1999.
“Translation and Stability of mRNA,” San Francisco Symposium 99, San Francisco, CA, October 11, 1999.
“Drug Discovery – The Biotech Industry & Isis,” Davidson Partners, Cleveland, OH, October 14, 1999.
1998
“Progress in Antisense Based Therapeutics,” International Business Conferences, “5th Annual Antisense Conference,” Hotel Del Coronado, CA, February 2-3, 1998.
“The Impacts of Molecular Biology on Drug Discovery and Development,” Yale University School of Medicine, New Haven, CT, February 10, 1998.
“Isis Pharmaceuticals“ CS First Boston Biotechnology & Pharmaceutical Conference, New York, NY, February 25, 19978.
“Isis Pharmaceuticals“ Cowen & Company Eighteenth Annual Health Care Conference, Boston, MA, March 9-10, 1998.
“Progress in Antisense Based Therapeutics,” Baylor College of Medicine – 1998 Alumni Scientific Symposium, Houston, TX, April 18, 1998.
“Progress in Antisense Based Therapeutics,” 45th Annual Meeting of Association of University Anesthesiologists, Hyatt Regency San Francisco, San Francisco, CA, May 7, 1998.
“The Second Century of the Drug Discovery and Development Industry,“ Fourteenth Annual California Biotechnology Conference, Issues in Drug Development: Laboratory to Formulary, Hyatt Regency, La Jolla, CA, June 3, 1998
“Isis Pharmaceuticals“ Goldman, Sachs & Co., Nineteenth Annual Healthcare Conference, Silverado Country Club & Resort, Napa, CA, June 9-11, 1998.
“Progress in Antisense Based Therapeutics,” SMART Program, Baylor College of Medicine, Houston, TX, July 1, 1998.
“Antisense Technology,” XIIIth International Congress of Pharmacology: From Molecular to Integrative Pharmacology: The IUPHAR Gateway to the 21st Century, Munich, Germany, July 26-31, 1998.
“Progress in Understanding and Proving Mechanisms of Antisense,” Nature Biotechnology Antisense ’98: Targeting the Molecular Basis of Disease, Mount Royal Hotel, London, UK, October 8-9, 1998.
“Properties of Human RNase H Type 2,” Ribonucleases H: Tools and therapeutic Targets, Biarritz, France, October 18-20, 1998.
“Introduction to Antisense,” MTH’s First Antisense Conference Prospects for Antisense Drugs, The Harvard Club, New York, NY, November 18, 1998.
“Molecular Mechanisms of Antisense Drugs,” National Institutes of Health,“ Third NIH Symposium on Therapeutic Oligonucleotides: Discovery and Milestone Achievement,” Bethesda, MD, December 4, 1998.
1997
“Progress in Antisense Therapeutics,” Ciba Foundation Symposium No. 209 – Oligonucleotides as Therapeutic Agents, London, England, January 6-9, 1997.
“Progress in Antisense Therapeutics,” Ciba Foundation Open Meeting – Oligonucleotides as Therapeutic Agents, London, England, January 10, 1997.
“Progress in Antisense Therapeutics, Proof of Mechanism,” IBC’s Fourth Annual International Symposium on Oligonucleotide- and Gene Therapy-Based Antisense Therapeutics, Wyndham Emerald Plaza Hotel, San Diego, CA, February 6-7, 1997.
“Incentives in Drug Development – Good Practices in Drug Development,” 36th International Industrial Pharmacy Conference, Barton Creek Conference Center, Austin, TX, February 24-27, 1997.
“Antisense-Based Therapies,” 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Town & Country Hotel, San Diego, CA, March 5-8, 1997.
“Isotype Selective Inhibition of Members of Multi-Gene Families Using Antisense Drugs,” 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Town & Country Hotel, San Diego, CA, March 5-8, 1997.
“Advances in Clinical Trials of Antisense Drugs,” American Society for Pharmacology and Experimental Therapeutics, Town & Country Hotel, San Diego, CA, March 8, 1997.
“Antisense Therapeutics: Basic Principles,” Society of Toxicology 36th Annual Meeting – Making Sense of Antisense, Cincinnati Convention Center, Cincinnati, OH, March 9, 1997.
“A Perspective on the Future,” Society of Toxicology 36th Annual Meeting – Making Sense of Antisense, Cincinnati Convention Center, Cincinnati, OH, March 9, 1997.
“Isis Pharmaceuticals,” Cowen & Company Seventeenth Annual Health Care Conference, Boston, MA, March 9-12, 1997.
“Progress in Antisense Based Therapeutics,” 1997 GSA Career Forum, University of Nebraska Medical Center, Omaha, NE, March 28, 1997.
“Novel Alliance Structures: The Isis-Boehringer Ingelheim Experience,” Allicense ’97 – Biotechnology Comes of Age, Ritz-Carlton, San Francisco, CA, April 24, 1997.
“Understanding Antisense Mechanisms May Lead to Important Therapeutics,” Nature Biotechnology Antisense ’97: Targeting the Molecular Basis of Disease, Hyatt Regency, Cambridge, MA, May 1-2, 1997.
“Isis Pharmaceuticals,” Alex Brown’s 22nd Annual Health Care Conference, Renaissance Harborplace Hotel, Baltimore, MD, May 5, 1997.
“Understanding Antisense Mechanisms,” Nature Biotechnology Symposium, Baylor College of Medicine, Houston, TX, May 2, 1997.
“Progress in Antisense Based Therapeutics,” 4th International Conference on Drug Absorption, Edinburgh, Scotland, June 13, 1997.
“Progress in Antisense Based Therapeutics,” Controlled Released Society, Inc., “Pharmaceutical Approach to Oligo & Gene Therapy,” Stockholm, Sweden, June 15, 1997.
“Progress in Antisense Based Therapeutics,” Health Canada, Ottawa, Canada, June 18, 1997.
“Progress in Antisense Based Therapeutics,” SMART Program, Baylor College of Medicine, Houston, TX, July 7, 1997.
“Progress in Antisense Based Therapeutics,” National Institutes of Health, “Future Needs and Developments in Antisense Technology,” Bethesda, MD, September 25, 1997.
“Progress in Antisense Based Therapeutics,” Post Graduate Research Conference, University of Kentucky, KY, October 10, 1997.
“The Molecular Biology of Lung Cancer,” Seventh Annual Lung Cell Biology Symposium, University of Boston Medical Center, Cape Cod, MA, October 27, 1997.
“Progress in Antisense Based Therapeutics,” National Institutes of Health, “Second NIH Symposium on therapeutic Oligonucleotides: Targeting transcription factors and signaling pathways,” Bethesda, MD, December 5, 1997.
“Molecular Mechanisms of Antisense Drugs,” National Institutes of Health, “Second NIH Symposium on Therapeutic Oligonucleotides: Targeting transcription factors and signaling pathways,” Bethesda, MD, December 5, 1997.
“Optimizing the Impact of Genomics on Drug Discovery and Development,” Global Business Research, Ltd. “Financing & Strategic Alliances for Emerging & Established Genomic Companies,” Le Meridian Hotel, San Diego, CA, December 10-11, 1997.
1996
“Advances in Antisense Oligonucleotide-bases Therapeutics,” Miami Bio/Technology Winter Symposium, Advances in Gene Technology: Therapeutic Strategies in Molecular Medicine, Marina Marriott, Ft. Lauderdale, FL, February 10-14, 1996.
“Antisense Technology,” IBC Conference, Third Annual Conference on Oligonucleotide & Gene Therapy-Based Antisense Therapeutics, Hotel Del Coronado, San Diego, CA, February 15-16, 1996.
“Isis Pharmaceuticals – Genomics & Antisense,” and “Isis Pharmaceuticals,” Cowen 16th Annual Health Care Conference, Copley Marriott, Boston, MA, March 11-12, 1996.
“Progress in Antisense Therapeutics,” University of Massachusetts Medical School, Frontiers in Molecular Therapeutics Research Symposium, Amphitheater III, Worchester, MA, April 8, 1996.
“Advances in Antisense Drug Discovery,” UCLA Research Symposium, Westwood, CA, April 17, 1996.
“Modern Drug Discovery Using Recombinant DNA Technology,” UCSD Undergraduate Seminar, San Diego, CA, April 29, 1996.
“Molecular Mechanisms of Antisense Drugs,” International Congress on Therapeutic Oligonucleotides, Rome, Italy, June 9-12, 1996.
“Oligonucleotides; a new generation of pharmaceutical agents,” Baylor College of Medicine, Smart Program, Houston, TX, July 17, 1996.
“NewsMakers in the Biotech Industry,” The Carson Group and BioCentury Publications Inc. September 5, l996.
“Antisense molecules for Combating Viral Infections,” Society for General Microbiology‘s 135th Ordinary Meeting at the University of Essex, Cells & Cell Surfaces Symposium, New and Novel Approaches to Treating Microbial Infections, September 11, 1996.
“Antisense Applications in Cancer Therapy,” Cancer Drug Discovery: Gene expression as a Drug Target Conference, University College Dublin, Ireland, September 14-18, 1996.
“Progress in Antisense Therapeutics,” Keynote Lecture, Medical USC-Ann. Student Research Day, November 1, 1996.
“Pharmacology of Antisense Oligonucleotides,” Seminar at GeneMedicine, Houston, TX, November 11-13, 1996.
1995
“Oligonucleotide Therapeutics,” University of California Los Angeles, Biotechnology Forum, CA, February 7, 1995.
“Oligonucleotide Therapeutics,” 1995 American Association of Pharmaceutical Scientists/American College of Clinical Pharmacology Joint Symposium, Catamaran Hotel, San Diego, CA, February 8, 1995.
“Oligonucleotide Therapeutics,” IBC Second 2nd Annual Oligonucleotides Conference, Hotel Del Coronado, San Diego, CA, February 9, 1995.
“Isis Pharmaceuticals,” Cowen & Co. Fifteenth Annual Health Care Conference, Marriott Copley Place Boston, MA, March 8, 1995.
“Progress in Oligonucleotide Therapeutics,” 86th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, March 19, 1995.
“Oligonucleotide Therapeutics,” Wadham College, University of Oxford International Symposium on Practical Approaches to the Regulation of Gene Expression: Progress in Neuroscience, March 27, 1995.
“Oligonucleotide Therapeutics,” 57th Nottingham Easter School in Agricultural Science, University of Nottingham, Leicestershire, UK, March 28, 1995.
“Isis Pharmaceuticals,” The Carson Group and BioCentury Publications, Inc., Fourth Clear Route Investor Conference, Macklowe Hotel & Conference Center, New York, NY, April 4,1995.
“Isis Pharmaceuticals,” Baylor SMART Program, Houston, TX, June 16, 1995.
“Pharmacokinetic Properties of Novel Antisense Oligonucleotides,” 1995 Gordon Research Conference on Drug Metabolism, Holderness School, Plymouth, NH, July 12, 1995.
“A Look at the Pharmaceutical Industry in the 21st Century,” Vector Securities Healthcare Conference, Cambridge University, England, September 13, 1995.
“Antisense Technology,” Vector Cambridge Conference ’95, Cambridge University, England, September 13, 1995.
“Isis Pharmaceuticals,” Cowen 8 Co. 10th Annual Biotech Conference, Ritz Carlton Hotel, San Francisco, CA, September 28, 1995.
“Antisense Technology,” Finch University/Chicago Medical School, Chicago, IL, October 25, 1995.
Mehta & Isaly Conference, Pharma with Health, Zurich, Switzerland, November 1, 1995.
“Antisense Technology,” Antisense Symposium, Tsukuba, Japan, November 6, 1995.
“Pharmacological Properties of Antisense Technology,” Antisense Symposium, Tsukuba, Japan, November 6, 1995.
1994
“Isis Pharmaceuticals,” Bums McClellan Roundtable, Westin St. Francis Hotel, San Francisco, CA, January 5, 1994.
“Isis Pharmaceuticals,” The Carson Group and BioCentury Publications, Inc., Tomorrow’s Leaders in the Biotech Industry, Macklowe Hotel & Convention Center, New York, NY, January 24, 1994.
“Advances in Oligonucleotide Therapeutics,” Markey Cancer Center Seminar Series, University of Kentucky, Lexington, KY, March 11, 1994.
“Isis Pharmaceuticals,” 14th Annual Cowen & Company Health Care Conference, Marriott Copley Place, Boston, MA, March 13-16, 1994.
“Isis Pharmaceuticals,” Lehman Brothers Selected Growth Stocks Conference, Phoenician Hotel, Scottsdale, AZ, April 8, 1994.
“Oligonucleotide Therapeutics,” ASPET Symposium, Anaheim Hilton Hotel, Anaheim, CA, April 28, 1994.
The CEO Panel, “Biotech in the New Health Care Environment,” Paine Webber Biotech Conference 1994, Hyatt Regency Hotel, La Jolla, CA, May 19, 1994.
“Advances in Oligonucleotide Therapeutics,” Sixth International Antiviral Symposium, Nice Acropolis Congress Center, Nice, France, June 10, 1994.
Panel Discussion: “Update on Antisense and Oligonucleotide Therapeutics,” CA Technology Stock Letter Gene 8 Cell Therapy Investment Conference, Hyatt Regency, San Francisco Airport, San Francisco, CA, June 14, 1994.
“Isis Pharmaceuticals,” Russell-Welsh BioPortfolio Seminar, Marriott Hotel, Houston, TX, June 28, 1994.
“Advances in Oligonucleotide Therapeutics,” SMART Program, Baylor College of Medicine, Houston, TX, June 29, 1994.
“Oligonucleotide Therapeutics,” Xllth International Congress of Pharmacology, Palais des Congres de Montreal, Montreal, Quebec, July 27, 1994.
“Oligonucleotide Therapeutics,” ASTRA Workshop on Novel, Therapeutical Approaches Based on Biotechnology, Vedbaek, Denmark, September 11-14, 1994.
“Antisense Technology,” Plenary Session, American Association of Pharmaceutical Scientists, 9th Annual Meeting and Exposition, San Diego Convention Center, San Diego, CA, November 7, 1994.
“Pharmacological Properties of Oligonucleotides,” Symposium on Oligonucleotide Therapeutics: Discovery, Chemistry & Biology, American Association of Pharmaceutical Scientists, 9th Annual Meeting and Exposition, San Diego Convention Center, San Diego, CA, November 8, 1994.
“Pharmacodynamics and Pharmacokinetics of Novel Chemical Classes of Oligonucleotides,” Symposium on Antisense DNA Technology: Pharmacokinetics & Pharmacodynamics, American Association of Pharmaceutical Scientists, 9th Annual Meeting and Exposition, San Diego Convention Center, San Diego, CA, November 8, 1994.
1993
“Isis Pharmaceuticals,” Hambrecht & Quist 11th Annual Life Sciences Conference, Westin St. Francis Hotel, San Francisco, CA, January 11, 1993.
“Oligonucleotide Therapeutics, Miami biotechnology Winter Symposium, Fountainebleau Hilton Hotel, Miami, FL, January 21,1993.
“Progress in Clinical Application of Antisense,” BioEast ’93, Washington, D.C., January 25, 1993.
“Cancer Research at Isis,” Cowen & Company 13th Annual Health Care Conference, Marrion Copley Place, Boston, MA, March 14-16, 1993.
“Oligonucleotide Therapeutics,” Keystone Symposia, Snowmass, CO, March 25, 1993.
“Oligonucleotide Therapeutics,” Baylor College of Medicine, Department of Pharmacology, Houston, TX, April 6, 1993.
“Anticancer Oligonucleotide Therapeutics,” Symposium on Strategies for Utilization of Antisense Molecules or Ribozymes as Specific Anticancer Agents, American Association for Cancer Research, 84th Annual Meeting, Orlando, FL, May 19-23, 1993.
“Regulation of Inflammatory Mediatom and the Therapeutic Utility of Oligonucleotides,” 1993 Congress on Cell 8 Tissue Culture, Town & Country Hotel, San Diego, CA, June 5-9, 1993.
“Regulation of Inflammatory Mediators & the Therapeutic Utility of Oligonucleotides,” SMART Program, Baylor College of Medicine, Houston, TX, June 21, 1993.
“Oligonucleotide Therapeutics,” Biointernational Conference ’93, Sheraton Conference & Exhibition Center, Houston, TX, August 25, 1993.
“The Evolution of the Revolution: Biotechnology in Transition,” Analytical Instrument Association 1993 Senior Management Conference, Stouffers Vinoy Hotel, St. Petersburg, FL, October 10-12, 1993.
“Oligonucleotide Inhibitors of Viral Replication,” Cambridge Healthtech Institute New Antivirals Meeting Omni Royal Hotel, New Orleans, LA, November 1-2, 1993.
“Oligonucleotide Therapeutics,” 13th International Symposium on HPLC of Proteins, Peptides and Polynucleotides, Hyatt Regency Hotel, San Francisco, CA, December 3, 1993.
“Oligonucleotides as Potential Therapeutic Agents,” IBC Conference on Commercializing Oligonucleotide-Based Therapeutics, Hotel Del Coronado, San Diego, CA, December 6, 1993.
“Oligonucleotide Anticancer Therapeutics,” MCR Cell Signaling & Cancer Treatment Conference, El San Juan Hotel, San Juan, Puerto Rico, December 9, 1993.
1992
“Isis Pharmaceuticals,” Hambrecht & Quist 10th Annual Life Sciences Conference, The Westin Saint Francis Hotel, San Francisco, CA, January 8-8, 1992.
“Isis Pharmaceuticals,” Lehman Brothers Selected Growth Stock Conference, Scottsdale Princess, Scottsdale, AZ, March 18-20, 1992.
“Phases of Development,” UCSD Core Technologies & Business Strategies Meeting, Issues Affecting the Growing Biotechnology Company, La Jolla, CA, May 20,1992.
“Oligonucleotide Therapeutics,” SMART Program, Baylor College of Medicine, Houston, TX, June 23, 1992.
“The Isis Strategy to Exploit a Broadly Enabling Technology: Antisense,” BioJapan ’92 Symposium (organized by the Japan Bioindustry Association), Pacifico Yokohama, Japan, August 28, 1992.
“Oligonucleotide Therapeutics: An Introduction,” The Philadelphia Biotechnology Meeting Strategies for Product Design 8 Development, The Radisson Hotel, Philadelphia, PA, September 22-24, 1992.
“Anticancer Oligonucleotide Therapeutics,” San Diego Regional Cancer Center International Conference on Gene Therapy of Cancer, Hotel Del Coronado, San Diego, CA, November 5-7,1992.
“Biopharmaceuticals: Facility Needs,” Gensler & Associates Architects, Irvine, CA, November 20, 1992.
“Antisense Oligonucleotides as Probes for Signal Transduction,” Thirteenth Annual Southeastern Pharmacology Society Meeting, Charleston, SC, September 30 – October 2, 1992.
“Anticancer Oligonucleotide Therapeutics,” University of California San Diego, Department of Pharmacology, San Diego, CA, December 9, 1992.
1991
“Issues and Obstacles in the Pharmaceutical Development of Oligonucleotides,” Lineberger Cancer Center, Chapel Hill, NC, March 21-22, 1991.
“Issues and Obstacles in the Pharmaceutical Development of Oligonucleotides,” ASPET Symposium on Antisense Therapeutics, 1991 Meeting of the American Society of Clinical Pharmacology and Therapeutics, San Antonio, TX, March 13-15, 1991.
“Venture Capital,” Rice University MBA Graduate Program, Houston, TX, March 26, 1991.
“Pharmaceutical Strategic Alliances,” In Vivo and Communitech Market Intelligence Conference, Pierre Hotel, New York, NY, September 23-24, 1991.
“Oligonucleotide Therapeutics,” University of California San Diego, Department of Chemistry Seminar, San Diego, CA, September 30, 1991.
“Making Sense of Antisense: The ISIS Approach,” Cowen & Company Sixth Annual Emerging Health Care Conference, Ritz Carlton Hotel, San Francisco, CA, October 2,1991.
Inflammation, Rome Cavalieri Hilton, Rome, Italy, October 6-11, 1991.
“Oligonucleotide Therapeutics,” Ciba-Geigy CRL 14th Fall Seminar, Basel, Switzerland, October 25, 1991.
1990
“The Signal Transduction Processes for LTD4 Receptors,” University of California Los Angeles, Department of Cellular and Molecular Biology Seminar Series, Los Angeles, CA, October 16, 1990.
“Symbiosis in Innovation,” Ernst & Young Venture Forum, San Francisco, CA, October 26,
1990.
“Issues and Obstacles in the Pharmaceutical Development of Oligonucleotides,” IBC Conference on Developments in Antisense Technology for Commercial Applications in Human Therapy and Agriculture, Wyndham Franklin Plaza Hotel, Philadelphia, PA, November, 1990.
“Isis Pharmaceuticals” Robert Stephens & Company 1990 Medical Conference, The Pierre Hotel, New York, NY, November 28, 1990.
1989
“Studies on the Structure and Function of Ubiquitin,” The University of Texas Medical Center, San Antonio, TX, January 25, 1989.
“Antisense Oligonucleotides: A New Paradigm for Drug Discovery,” Bioventure View Venture Lunch Program, Hotel Sofitel, Redwood Shores, CA, April 7, 1989.
“Antisense Oligonucleotides: A New Paradigm for Drug Discovery,” Alex Brown & Sons’ Health Care Seminar, Hyatt Regency, Baltimore, MD, May 9, 1989.
“LTD4 Signal Transduction Processes,” Annual Meeting of the Swedish Biochemical Society, Linkoping, Sweden, September 8, 1989.
“The LTD4 Signal Transduction Processes,” The Karolinska Institutet, Stockholm, Sweden, September 12, 1989.
“The Signal Transduction Processes for LTD4 Receptors,” International Symposium on Trends in Eicosanoids, Grant Hotel Victoria-Jungfrau, Interlaken, Switzerland, September 14, 1989.
“Antisense Drugs: The Next Area for Biotechnology Breakthrough,” The Wilkerson Group 14th Annual Symposium on Business and Medicine, Grand Hyatt Hotel, New York, NY, September 19, 1989.
1988
“Update on Chemotherapeutic Agents,” Pennsylvania Hospital, Philadelphia, PA, February 9, 1988.
“Leukotriene Receptors and Signal Transduction Processes,” University of Pennsylvania, PA, February 9, 1988.
“Enhancing Academic and Industrial Interactions,” 40th Anniversary of Baylor College of Medicine, Houston, TX, February 17, 1988.
“Basic Pharmacology of Leukotrienes,” American Society for Clinical Pharmacology and Therapeutics 89th Annual Meeting, San Diego, CA, March 11,1988.
“Ubiquitin: Structural and Biochemical Studies,” University of Virginia, Charlottesville, VA, May 6, 1988.
“Knowledge and Power: Biotechnology,” Library of Congress Symposium, Washington, D.C., June 16, 1988.
“Structure Activity of Ubiquitin Relationships,” Stanford University, Stanford, CA, July 11, 1988.
“Studies on the Structure and Function of Ubiquitin,” Smith Kline & French Laboratories Research Symposium VI, Valley Forge, PA, November 1, 1988.
“Studies on the Structure and Function of Ubiquitin,” Genelabs, Inc., Redwood City, CA, November 11, 1988.
1987
“Cellular and Molecular Aspects of Inflammation,” Co-chairman, Smith Kline & French Laboratories Research Symposia Series V, Valley Forge, PA, April 21-23, 1987.
“Cellular and Molecular Aspects of Inflammation,” LTD4 Receptors and Signal Transduction Processes,Valley Forge, PA, April 23,1987.
“LTD4 Receptors and Signal Transduction Processes, Baylor College of Medicine, Houston, TX, June 23, 1987.
“LTD4 Receptors and Signal Transduction Processes and Antagonists,” New York Academy of Sciences, Conference on the Biology of Leukotrienes, PA, June 28-July 1, 1987.
“Studies on Leukotriene Transduction Processes and 5-Lipoxygenase,” the Gordon Conference, NH, August 4, 1987.
“The Way Forward – Lipoxygenase Inhibitors,” International Conference on Drugs Affecting Leukotrienes and Lipoxygenase Products; A Potential Fulfilled?, London, England, September 30, 1987.
“Studies on the Structure and Function of Ubiquitin,” Centro Biologia Molecular, Madrid, Spain, September 25, 1987.
1986
“New Frontiers in the Study of Gene Functions,” Co-chairman, Smith Kline & French Laboratories Research Symposia Series IV, Valley Forge, PA, April 8-10, 1986.
Pharmacology of Auranofin, Auranofin Symposium, Amsterdam, June 19-22, 1986.
Molecular Pharmacology of Auranofin, A.B. Leo, Sweden, June 22-24, 1986.
“Health and Wholeness,” Chautauqua Institution, Chautauqua, NY, August 11, 1986.
“Recent Advances in Leukotriene and Antagonists,” American Society for Pharmacology and Experimental Therapeutics, Baltimore, MD, August 17-21, 1986.
1985
“New Insights into Cell and Membrane, Transpod Processes,” Co-chairman, Smith Kline & French Laboratories Research Symposia Series III, Philadelphia, PA, March 12-14, 1985.
“Molecular Pharmacology of Leukotrienes,” University of California Los Angeles, CA, May 1-3, 1985.
R&D and Gl Disease-Overview of R&D at SK&F. Cimetidine 85- New insights from a decade of continuing research, 8/8-9/1985; 8/12-13/1985, Denver, CO.
1984
“Receptor Regulation: New Strategies for Drug Development,” Smith Kline & French Symposia Series II, Mechanisms of Receptor Regulation, Philadelphia, PA, February 28 – March 1,1984.
Keynote Speaker, Baylor College of Medicine, First Year Student Convocation, Houston, TX, August 4, 1984.
“Biotechnology: history, impact, future,” Keynote Speaker, World Affairs Council, Philadelphia, PA. October 10, 1984.
1983
Co-Chairman, Smith Kline & French Laboratories Research Symposia Series I, “Dopamine Receptor Agonists,” Philadelphia, PA, February 23-24, 1983.
Fourth Annual Healthcare Seminar, Goldman, Sachs 8 Co., New York, NY, March 2, 1983.
“Sequence and Topology-Specific Attack on DNA and Chromatin,” 7th Annual Symposium on The Development of Target-Oriented Anticancer Drugs, University of North Carolina at Chapel Hill, NC, March 24-25, 1983.
Future Role of Pharmaceutics Research in Drug Discovery, Centennial Symposium, “Pharmaceutical Science: Its Past and Its Future.” University of Wisconsin-Madison, School of Pharmacy, WI, October 3, 1983.
“The Financial Analysts Presentation,” Morgan Stanley, New York, N.Y., October 26,1983.
1982
“DNA: A Series of Allosterically Interacting Receptors for Anti-Cancer Drugs,” George Washington University, Washington, D.C., April 9, 1982.
“The Molecular Pharmacology of Anthracyclines,” University of Virginia, VA, May 17, 1982.
“Molecular Mechanisms of Action of Auranofin and Other Gold Complexes as Related to their Biological Activities,” Second Worldwide Auranofin Symposium, San Francisco, CA, August 2-5, 1982.
“The Financial Analysts,” SmithKline Beckman Corporation, Philadelphia, PA, November 11, 1982.
1981
Chairman, Biochemical Pharmacology Session, American Association for Cancer Research, Washington, D.C., May, 1981.
“Pulmonary Toxicities of Cytotoxic Agents in Animals,” Conference on long term tissue effects of cancer treatment, Bethesda, MD, April 13-15, 1981.
“Molecular Pharmacology of the Anthracyclines,” SK&F Labs, August 4, 1981.
“Substrate Effects on the Interaction of Bleomycin and Related Antibiotics on DNA,” 28th IUPAC Congress, Vancouver, Canada, August 24, 1981.
“A Comparison of the Molecular Pharmacology of Gold and Platinum Complexes,” Worldwide Auranofin Symposium, Therapeutic Innovation in Rheumatoid Arthritis: Montreal, Canada, October 20-21, 1981.
“DNA: A Series of Allosterically Interacting Drug Receptors,” Julius W. Stummer Memorial Lecture, Philadelphia College of Pharmacy and Science, Philadelphia, PA, December 3, 1981.
“Studies on the Molecular Pharmacology of the Bleomycins,” University of Pennsylvania Medical School, PA, December 14, 1981.
1980
“Emerging Cisplatinum Use in Head, Neck and Other Tumors,” Cisplatin and Chemotherapy Mini-Symposium, Honolulu, HI, February 22, 1980.
“Other New Cancer Drugs on the Horizon,” Cisplatin and Chemotherapy Mini-Symposium, Honolulu, HI, February 22, 1980.
“Molecular Pharmacology of Anthracyclines,” Upstate Medical Center, Syracuse, NY, March 14, 1980.
“The Financial Analysts,” The Anticancer Therapy Development Program at Bristol- Meyers, New York, NY, January 17, 1980.
“Molecular Pharmacology of Several Antitumor Antibiotics,” American Chemical Society Meetings, Houston, TX, May 25, 1980.
“Newer Aspects of the Mechanism of Action and Pharmacology of Bleomycin and Analogs,” Symposium on New Developments in Pharmacology on Antineoplastic Agents at the Joint Congress of the International Society of Hematology and International Society of Blood Transfusions, Montreal, Canada, August 21, 1980.
“Studies on the Molecular Pharmacology of the Bleomycins,” New York University Medical School, New York, NY, October 24, 1980.
“The Financial Analysts,” SmithKline Corporation, Philadelphia, PA, November 13, 1980.
1979
“Structure Activity Relationships of Anthracyclines,” ACS Meeting, Syracuse, NY, January 17, 1979.
“Bleomycin Pharmacology,”: Medical Center Oncology Grand Rounds Conference, Harper Grace Hospital, Detroit, MA, March 1,1979.
“Molecular Pharmacologic Studies on the Anthracyclines,” Yale University, New Haven, CT, March 16, 1979.
“The Bristol-Meyers Anticancer Drug Research and Development Program,” Symposium on Anticancer Therapy, Stockholm, Sweden, April, 1979.
“Studies on Anthracycline Molecular Pharmacology,” A.B. Leo, Helsingborg, Sweden, April, 1979.
“Tallysomycin, A Third Generation Bleomycin Analog,” U.S/Japan Cancer Treaty Meeting, San Francisco, CA,May 21, 1979.
Co-chairman, Anthracycline Workshop, Norfolk, VA, June 13-14, 1979.
“Bleomycin Analogs,” Upstate Medical Center, Syracuse, NY, September 17, 1979.
Co-chairman, Cisplatin – Current Status and New Developments Symposium, Atlanta, GA, September 26-28, 1979.
“Cardiopulmonary Toxicities of Antineoplastic Agents,” 11th International Congress of Chemotherapy and 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, October 2, 1979.
“Recent Advances in Antineoplastic Chemotherapy,” Annual Post-Graduate Review Course on Ophthalmology, Syracuse, NY, November 30,1979.
“Molecular Pharmacology of the Anthracyclines,” Yale Symposium, New Haven, CT, November 8-9, 1979.
“Pharmacology Review of Antineoplastic Drugs Currently Being Researched,” American Society of Hospital Pharmacists Annual Meeting, Las Vegas, NV, December 3, 1979.
1978
“Bleomycin,” Pharmacology Department Seminar, Baylor College of Medicine, Houston, TX, March 7, 1978.
“Recent Advances in the Study of Clinical Pharmacology of Bleomycin,” Workshop on Clinical Pharmacology of Antineoplastic Drugs, Lunteren, Netherlands, April 24-25, 1978.
“A Review of the Clinical Pharmacology of Cis Platinum” Workshop on Clinical Pharmacology of Anti-Neoplastic Drugs, Lunteren, Netherlands, April 24-25, 1978.
“Recent Studies on Bleomycin,” National Cancer Institute, May 16, 1978.
“Bleomycin, Recent Studies on Several Aspects,” Baltimore Cancer Research Center, June 13, 1978.
Chairman-Cancer Chemotherapy Section, Gordon Conference on Medicinal Chemistry, New London, NH, August 1-8, 1978.
“Antineoplastic Agents which Degrade DNA,” Gordon Conference on Medicinal Chemistry, New London, NH, August 1-8, 1978.
“Antineoplastic Drug Development in the Pharmaceutical Industry,” Symposium on Cancer Drug Development, American Society of Experimental Pharmacology and Therapeutics Annual Meeting, Houston, TX, August 18, 1978.
Chairman-New Anthracyclines – I – NCI-EORTC Symposium, Brussels, Belgium, September 7-8,1978.
“Studies on the Molecular Pharmacology of Anthracyclines,” Albany Medical College, NY, September 15, 1978.
Co-chairman of the NCCP-Bristol Laboratories Mitomycin C Symposium, San Francisco, CA, September 20-21, 1978.
“Mitomycin C – An Overview,” NCCP-Bristol Laboratories, Mitomycin C Symposium, San Francisco, CA, September 20-21, 1978.
“A Summary of the Clinical Pharmacology of Bleomycin,” Chemotherapy Foundation Symposium III (New Developments and Changing Concepts in Cancer Chemotherapy), Barbizon Plaza Hotel, New York, NY, October 27-28,1978.
Co-chairman of the Drug Effects on the Cell Nucleus Symposium, Houston, TX, November 8-9, 1978.
“Biochemical Effects of Drugs on the Cell Nucleus,” Symposium, Houston, TX, November 8-9, 1978.
“Cancer Chemotherapy – Market and Products opportunities,” The Financial Analysts Presentation, Philadelphia, PA, November 13-14, 1978.
1977
“Structure Activity Relationships of Anthracyclines,” Upstate Medical Center, Syracuse, NY, March 28, 1977.
“Antitumor Antibiotics,” ACP Medical Oncology Review Course, Pasadena, CA, October 6, 1977.
“Recent Asdvances in Cancer Molecular Biology,” Eastern ACP, October 13-14, 1977.
Co-chairman of the NCCP-Bristol Laboratories, Bleomycin Symposium, Oakland, CA, October 20-21, 1977.
“BU-2231, A Third Generation Bleomycin,” Bleomycin Symposium, Oakland, CA, October 20-21, 1977.
“Bleomycin Clinical Pharmacology, Bleomycin,” Symposium Oakland, CA, October 20-21, 1977.
“Studies on Several New Anthracyclines,” Louisiana State University, LA, August 1977.
“Studies on the Clinical Pharmacology of Bleomycin,” Proc. of U.S./Japan Joint Cancer Symposium, San Francisco, CA, May 12-13, 1977.
1976
“Bleomycin, A Review,” Topics in Clinical Oncology Symposium, Portland, OR, March 18, 1976.
“New Studies on Bleomycin,” Upstate Medical Center, Syracuse, NY, October 25, 1976.